EPA Identifies Safer Substitutes for Toxic Flame Retardants

Following earlier action by the EU, the US Environmental Protection Agency (EPA) is planning to publish guidelines on safer alternatives to the flame retardants now used in consumer and commercial products, including building insulation and products with flexible polyurethane foam.

Flame retardant chemicals such as hexabromocyclododecane (HBCD) and pentabromodiphenyl ether (pentaBDE) raise concerns for human health and the environment including potential reproductive, developmental, and neurological effects and can be persistent, bioaccumulative, and toxic to aquatic organisms, EPA stressed in a statement.

The US agency has identified butadiene styrene brominated copolymer as a safer alternative to HBCD used in polystyrene building insulation. The substitute is currently in commercial production in the US.

EPA has identified oligomeric phosphonate polyol as a safer alternative to pentaBDE.

ECHA, the body that implements the EU's REACH legislation, is due to decide on July 9 whether exemptions can be granted to manufacturers of expanded polystyrene, EPS, to continue using HBCD as a flame retardant beyond the August 2015 phase-out deadline. Most international players are switching to the new non-halogen flame polymeric retardant PolyFR.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.